Manhattan Research names top product sites for docs

Share this article:

Two diabetes product sites – Merck's Januvia and Takeda's Actos – came in first and second, respectively, in a new study measuring physicians' web habits.

The study, conducted by Manhattan Research, ranked drug product sites based on visitation rates from primary care physicians. Merck had the most product sites on the list, at three, which included Gardasil's (#4) and Vytorin's (#6) websites. Pfizer's Chantix, a smoking cessation treatment, held the number three spot.

Actonel, an osteoporosis treatment marketed through a Proctor & Gamble and Sanofi-Aventis partnership, was ranked at number five. Seven through 10 are as follows:

7. Amitiza, a Sucampo Pharmaceuticals and Takeda product
8. Byetta, an Amylin and Lilly product
9. Avandia, a GlaxoSmithKline product
10. Aciphex, an Eisai and PriCara product

“This year's rankings show that market events, rather than just advertising alone, can be critical drivers to brand websites,” said Meredith Abreu Ressi, vice president of research at Manhattan Research, in a statement. “Pharmaceutical companies need to ensure that brand websites contain the latest, most accurate content possible and can be found relatively easily by physicians using search engines to research pharmaceutical information.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...